Incidence and risk factors for second cancers after autologous hematopoietic cell transplantation for aggressive non-Hodgkin lymphoma
- 1 January 2009
- journal article
- research article
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 50 (3) , 380-386
Abstract
Autologous hematopoietic stem cell transplantation (AHCT) for relapsed/refractory aggressive non-Hodgkin lymphoma (NHL) results in long-term disease-free survival in 40–50% of patients. The incidence of and risk factors for second cancer development in these patients have not been well studied. We analysed 372 patients with relapsed/refractory aggressive NHL who underwent AHCT from 1987 to 2006. Median age at AHCT was 50 years (range 19–70). Most patients (74%) received two chemotherapy regimens before transplant. High-dose chemotherapy consisted of etoposide and melphalan in 95% of patients and 16% received total body irradiation. Thirty-two patients (9%) developed a second cancer (19 hematologic, 13 solid tumors). The probability of second cancer at 3 and 10 years post-AHCT was 4.4% and 12.9%, respectively. When compared with the general population, the relative-risk of acute myeloid leukemia and new solid tumor was 13.2 (p < 0.0001) and 2.3 (p = 0.0013). Salvage therapy using mini-BEAM was significantly associated with second cancer development (p = 0.004). In conclusion, second cancers are a significant cause of late morbidity and mortality patients treated with AHCT with curative intent, and appear increased in patients exposed to mini-BEAM chemotherapy.Keywords
This publication has 31 references indexed in Scilit:
- Late Effects in Survivors of Hodgkin and Non-Hodgkin Lymphoma Treated with Autologous Hematopoietic Cell Transplantation: A Report from the Bone Marrow Transplant Survivor StudyTransplantation and Cellular Therapy, 2007
- Late non‐relapse mortality among adult autologous stem cell transplant recipients: a nation‐wide analysis of 1482 patients transplanted in 1990–2003European Journal of Haematology, 2006
- Late mortality in survivors of autologous hematopoietic-cell transplantation: report from the Bone Marrow Transplant Survivor StudyBlood, 2005
- Increasing Incidence of Late Second Malignancies After Conditioning With Cyclophosphamide and Total-Body Irradiation and Autologous Bone Marrow Transplantation for Non-Hodgkin’s LymphomaJournal of Clinical Oncology, 2005
- Long-term follow-up after autologous hematopoietic stem cell transplantation for low-grade non-Hodgkin lymphomaTransplantation and Cellular Therapy, 2005
- Treatment-Related Myelodysplasia and Acute Leukemia in Non-Hodgkin’s Lymphoma PatientsJournal of Clinical Oncology, 2003
- Myelodysplastic syndrome and acute myeloid leukemia after autotransplantation for lymphoma: a multicenter case-control studyBlood, 2002
- Secondary leukaemia and myelodysplasia after autografting for lymphoma: results from the EBMTBritish Journal of Haematology, 1999
- A Proportional Hazards Model for the Subdistribution of a Competing RiskJournal of the American Statistical Association, 1999
- Myelodysplasia and acute leukemia following high-dose chemotherapy and autologous bone marrow or peripheral blood stem cell transplantationBone Marrow Transplantation, 1999